- Home
- GERN vs MBUU Comparison
GERN vs MBUU Comparison
Compare GERN & MBUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- MBUU
- Stock Information
- Founded
- GERN 1990
- MBUU 1982
- Country
- GERN United States
- MBUU United States
- Employees
- GERN N/A
- MBUU N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- MBUU Marine Transportation
- Sector
- GERN Health Care
- MBUU Industrials
- Exchange
- GERN Nasdaq
- MBUU Nasdaq
- Market Cap
- GERN 700.6M
- MBUU 617.8M
- IPO Year
- GERN 1996
- MBUU 2014
- Fundamental
- Price
- GERN $1.17
- MBUU $32.43
- Analyst Decision
- GERN Buy
- MBUU Hold
- Analyst Count
- GERN 8
- MBUU 5
- Target Price
- GERN $3.71
- MBUU $34.25
- AVG Volume (30 Days)
- GERN 9.2M
- MBUU 129.6K
- Earning Date
- GERN 08-06-2025
- MBUU 08-28-2025
- Dividend Yield
- GERN N/A
- MBUU N/A
- EPS Growth
- GERN N/A
- MBUU N/A
- EPS
- GERN N/A
- MBUU N/A
- Revenue
- GERN $116,293,000.00
- MBUU $759,234,000.00
- Revenue This Year
- GERN $161.44
- MBUU N/A
- Revenue Next Year
- GERN $53.06
- MBUU $9.04
- P/E Ratio
- GERN N/A
- MBUU N/A
- Revenue Growth
- GERN 22264.04
- MBUU N/A
- 52 Week Low
- GERN $1.09
- MBUU $24.43
- 52 Week High
- GERN $4.89
- MBUU $47.82
- Technical
- Relative Strength Index (RSI)
- GERN 39.34
- MBUU 42.83
- Support Level
- GERN $1.20
- MBUU $34.34
- Resistance Level
- GERN $1.37
- MBUU $36.04
- Average True Range (ATR)
- GERN 0.08
- MBUU 1.25
- MACD
- GERN -0.01
- MBUU -0.30
- Stochastic Oscillator
- GERN 28.57
- MBUU 12.72
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About MBUU Malibu Boats Inc.
Malibu Boats is a leading designer and manufacturer of power boats in the United States. It is the market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a leading producer of sterndrive boats in the US in the 24- to 29-foot segment, in 2017 and Pursuit Boats, which makes high-end offshore and outboard motorboats, in 2018. In 2021, it purchased Maverick Boat Group, a top seller of flat fishing boats, including bay, dual-console, and center-console boats. Malibu has also expanded into boat trailers and accessories and in 2020 began producing its own engines (Monsoon) for its performance sport boats and now for Cobalt. Malibu's target market includes a wide range of water enthusiasts who embrace the active outdoor lifestyle.